Eisai and Biogen Self-Injected Alzheimer Drug Wins US Approval

Eisai Co. and Biogen Inc. received US regulatory approval for a new self-injected form of their Alzheimer’s drug Leqembi, in a move that could make a complicated treatment regimen more convenient for patients taking the drug long term.

The drug, which lowers levels of a toxic brain protein called amyloid, was approved in 2023 and is currently given as an infusion by a health-care provider every two weeks for 18 months. After that, patients can continue to get additional infusions every two or four weeks.